Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Other Working Capital Changes (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Other Working Capital Changes for 13 consecutive years, with $782000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 906.19% to $782000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $187000.0, a 172.76% increase, with the full-year FY2025 number at $187000.0, up 172.76% from a year prior.
  • Other Working Capital Changes was $782000.0 for Q4 2025 at Ekso Bionics Holdings, up from -$170000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $840000.0 in Q4 2022 to a low of -$663000.0 in Q3 2021.
  • A 5-year average of $83050.0 and a median of -$27500.0 in 2021 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: plummeted 1186.89% in 2021, then skyrocketed 2433.33% in 2022.
  • Ekso Bionics Holdings' Other Working Capital Changes stood at -$36000.0 in 2021, then surged by 2433.33% to $840000.0 in 2022, then plummeted by 47.62% to $440000.0 in 2023, then tumbled by 122.05% to -$97000.0 in 2024, then surged by 906.19% to $782000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Other Working Capital Changes are $782000.0 (Q4 2025), -$170000.0 (Q3 2025), and -$406000.0 (Q2 2025).